AIM ImmunoTech Inc

Financials

Flusso di cassa derivante dalle attività operative -3.96 M-2.36 M-1.53 M-5.08 M-1.99 M -10.96 M Flussi di cassa derivanti dalle attività di investimento 3.7 M898 K754 K296 K-95 K 1.85 M Liquidità derivante dalle attività di finanziamento 1.04 M660 K355 K6.65 M2.72 M 10.39 M Liquidità libera -4.07 M-2.42 M-1.76 M-5.08 M-2.08 M -11.34 M

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.

AIM

Financials

AIM ImmunoTech Inc

Notizie

AIM ImmunoTech modifica accordo di distribuzione azionaria rimuovendo il limite sulle vendite

Aimia Inc. non raggiunge le previsioni Q4 2025, azioni in rialzo

What's Going On With AIM ImmunoTech Stock Friday? - AIM ImmunoTech (AMEX:AIM)

AIM ImmunoTech completes rights offering, creates new preferred stock series

Indonesia Sees $11 Billion in Share Sales to Meet Free-Float Aim

AIM ImmunoTech al Virtual Investor Closing Bell: focus strategico sul cancro al pancreas

AIM ImmunoTech at Virtual Investor Closing Bell: Strategic Focus on Pancreatic Cancer

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories! - TipRanks.com

Bets on Surprise ECB Cut in 2026 Aim for 12-Fold Return

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

MedPal AI reports 16% prescription growth in December